Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: NON-SMALL CELL LUNG CANCER, . Treffer: 60

2020

Lindenmann, J; Fink-Neuboeck, N; Taucher, V; Pichler, M; Posch, F; Brcic, L; Smolle, E; Koter, S; Smolle, J; Smolle-Juettner, FM Prediction of Postoperative Clinical Outcomes in Resected Stage I Non-Small Cell Lung Cancer Focusing on the Preoperative Glasgow Prognostic Score.
Cancers (Basel). 2020; 12(1): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Moik, F; Zöchbauer-Müller, S; Posch, F; Pabinger, I; Ay, C Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer.
Cancers (Basel). 2020; 12(6): [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

2019

de Wit, S; Rossi, E; Weber, S; Tamminga, M; Manicone, M; Swennenhuis, JF; Groothuis-Oudshoorn, CGM; Vidotto, R; Facchinetti, A; Zeune, LL; Schuuring, E; Zamarchi, R; Hiltermann, TJN; Speicher, MR; Heitzer, E; Terstappen, LWMM; Groen, HJM Single tube liquid biopsy for advanced non-small cell lung cancer.
Int J Cancer. 2019; 144(12): 3127-3137. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Lastwika, KJ; Kargl, J; Zhang, Y; Zhu, X; Lo, E; Shelley, D; Ladd, JJ; Wu, W; Kinahan, P; Pipavath, SNJ; Randolph, TW; Shipley, M; Lampe, PD; Houghton, AM Tumor-derived Autoantibodies Identify Malignant Pulmonary Nodules.
Am J Respir Crit Care Med. 2019; 199(10):1257-1266 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Mohrherr, J; Haber, M; Breitenecker, K; Aigner, P; Moritsch, S; Voronin, V; Eferl, R; Moriggl, R; Stoiber, D; Győrffy, B; Brcic, L; László, V; Döme, B; Moldvay, J; Dezső, K; Bilban, M; Popper, H; Moll, HP; Casanova, E JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
Int J Cancer. 2019; 145(12):3376-3388 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Rao, S; Mondragón, L; Pranjic, B; Hanada, T; Stoll, G; Köcher, T; Zhang, P; Jais, A; Lercher, A; Bergthaler, A; Schramek, D; Haigh, K; Sica, V; Leduc, M; Modjtahedi, N; Pai, TP; Onji, M; Uribesalgo, I; Hanada, R; Kozieradzki, I; Koglgruber, R; Cronin, SJ; She, Z; Quehenberger, F; Popper, H; Kenner, L; Haigh, JJ; Kepp, O; Rak, M; Cai, K; Kroemer, G; Penninger, JM AIF-regulated oxidative phosphorylation supports lung cancer development.
Cell Res. 2019; [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Smolle, E; Leithner, K; Olschewski, H Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.
Thorac Cancer. 2019; [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Smolle, E; Pichler, M Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition.
Cancers (Basel). 2019; 11(2): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Sutic, M; Motzek, A; Bubanovic, G; Linke, M; Sabol, I; Vugrek, O; Ozretic, P; Brcic, L; Seiwerth, S; Debeljak, Z; Jakovcevic, A; Janevski, Z; Stancic-Rokotov, D; Vukic-Dugac, A; Jakopovic, M; Samarzija, M; Zechner, U; Knezevic, J Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small cell lung cancer (NSCLC)
TRANSL LUNG CANCER R. 2019; 8(6): 1000-+. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Veatch, JR; Jesernig, BL; Kargl, J; Fitzgibbon, M; Lee, SM; Baik, C; Martins, R; Houghton, AM; Riddell, SR Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations.
CANCER IMMUNOL RES. 2019; 7(6): 910-922. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2018

Buder, A; Hochmair, MJ; Schwab, S; Bundalo, T; Schenk, P; Errhalt, P; Mikes, RE; Absenger, G; Patocka, K; Baumgartner, B; Setinek, U; Burghuber, OC; Prosch, H; Pirker, R; Filipits, M Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
J THORAC ONCOL. 2018; 13(6): 821-830. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Frille, A; Leithner, K; Olschewski, A; Olschewski, H; Wohlkönig, C; Hrzenjak, A No erythropoietin-induced growth is observed in non-small cell lung cancer cells.
Int J Oncol. 2018; 52(2): 518-526.
Web of Science PubMed FullText FullText_MUG

 

Gantenbein, N; Bernhart, E; Anders, I; Golob-Schwarzl, N; Krassnig, S; Wodlej, C; Brcic, L; Lindenmann, J; Fink-Neuboeck, N; Gollowitsch, F; Stacher-Priehse, E; Asslaber, M; Gogg-Kamerer, M; Rolff, J; Hoffmann, J; Silvestri, A; Regenbrecht, C; Reinhard, C; Pehserl, AM; Pichler, M; Sokolova, O; Naumann, M; Mitterer, V; Pertschy, B; Bergler, H; Popper, H; Sattler, W; Haybaeck, J Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.
Eur J Cancer. 2018; 101(4):165-180 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kriegshäuser, G; Enko, D; Novy, M; Reitmayr, A; Loidl, A; Halwachs-Baumann, G; Oberkanins, C EGFR Mutational Profiling in Non-Small Cell Lung Cancer: The Clinical Performance of a Sensitive Reverse-Hybridization Assay.
Appl Immunohistochem Mol Morphol. 2018; 26(6):388-392
Web of Science PubMed FullText FullText_MUG

 

Mark, NM; Kargl, J; Busch, SE; Yang, GHY; Metz, HE; Zhang, H; Hubbard, JJ; Pipavath, SNJ; Madtes, DK; Houghton, AM Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.
Am J Respir Crit Care Med. 2018; 197(3):325-336 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Moll, HP; Pranz, K; Musteanu, M; Grabner, B; Hruschka, N; Mohrherr, J; Aigner, P; Stiedl, P; Brcic, L; Laszlo, V; Schramek, D; Moriggl, R; Eferl, R; Moldvay, J; Dezso, K; Lopez-Casas, PP; Stoiber, D; Hidalgo, M; Penninger, J; Sibilia, M; Győrffy, B; Barbacid, M; Dome, B; Popper, H; Casanova, E Afatinib restrains K-RAS-driven lung tumorigenesis.
Sci Transl Med. 2018; 10(446): [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Ryska, A; Berzinec, P; Brcic, L; Cufer, T; Dziadziuszko, R; Gottfried, M; Kovalszky, I; Olszewski, W; Oz, B; Plank, L; Timar, J NSCLC molecular testing in Central and Eastern European countries.
BMC Cancer. 2018; 18(1): 269-269. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Ryska, A; Buiga, R; Fakirova, A; Kern, I; Olszewski, W; Plank, L; Seiwerth, S; Toth, E; Zivka, E; Thallinger, C; Zielinski, C; Brcic, L Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group.
Oncologist. 2018; 23(12):e152-e158-e152-e158 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2017

Dandachi, N; Tiran, V; Lindenmann, J; Brcic, L; Fink-Neuboeck, N; Kashofer, K; Absenger, G; Bezan, A; Cote, RJ; Datar, R; Balic, M Frequency and clinical impact of preoperative circulating tumor cells in resectable non-metastatic lung adenocarcinomas.
Lung Cancer. 2017; 113(46):152-157
Web of Science PubMed FullText FullText_MUG

 

Fadejeva, I; Olschewski, H; Hrzenjak, A MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas.
Oncotarget. 2017; 8(70):115754-115773 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Gantenbein, N; Bernhart, E; Anders, I; Lindenmann, J; Fink-Neubock, N; Brcic, L; Gollowitsch, F; Stacher-Priehse, E; Rolff, J; Hoffmann, J; Reinhard, C; Popper, H; Sattler, W; Haybaeck, J Eukaryotic Translation Initiation Factors Impact Non-Small Cell Lung Cancer
J THORAC ONCOL. 2017; 12(1):S1141-S1142. [Poster]
Web of Science

 

Mehta, AK; Hua, K; Whipple, W; Nguyen, MT; Liu, CT; Haybaeck, J; Weidhaas, J; Settleman, J; Singh, A Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells.
Sci Signal. 2017; 10(496): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Wohlkoenig, C; Leithner, K; Olschewski, A; Olschewski, H; Hrzenjak, A TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1α.
Lung Cancer. 2017; 111(3):15-22
Web of Science PubMed FullText FullText_MUG

 

2016

Al-Zoughbi, W; Pichler, M; Gorkiewicz, G; Guertl-Lackner, B; Haybaeck, J; Jahn, SW; Lackner, C; Liegl-Atzwanger, B; Popper, H; Schauer, S; Nusshold, E; Kindt, AS; Trajanoski, Z; Speicher, MR; Haemmerle, G; Zimmermann, R; Zechner, R; Vesely, PW; Hoefler, G Loss of adipose triglyceride lipase is associated with human cancer and induces mouse pulmonary neoplasia.
Oncotarget. 2016; 7(23):33832-33840 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Leithner, K; Hirschmugl, B; Li, Y; Tang, B; Papp, R; Nagaraj, C; Stacher, E; Stiegler, P; Lindenmann, J; Olschewski, A; Olschewski, H; Hrzenjak, A TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers.
PLoS One. 2016; 11(6):e0157453-e0157453 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Shafirstein, G; Battoo, A; Harris, K; Baumann, H; Gollnick, SO; Lindenmann, J; Nwogu, CE Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions.
Ann Am Thorac Soc. 2016; 13(2):265-275 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2015

Fischer, C; Leithner, K; Wohlkoenig, C; Quehenberger, F; Bertsch, A; Olschewski, A; Olschewski, H; Hrzenjak, A Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Mol Cancer. 2015; 14(8):4-4 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Jakopovic, M; Cucevic, B; Plestina, S; Kukulj, S; Roglic, M; Smojver-Jezek, S; Chalfe, N; Korsic, M; Redzepi, G; Brcic, L; Popovic, F; Badovinac, S; Samarzija, M Efficacy and safety of erlotinib in squamous cell lung cancer
Journal of Thoracic Oncology, 2015:10 (9, Suppl 2). 2015; 10(9):S423-S424.-16th World Conference on Lung Cancer; SEP 6 - 9, 2015 ; Denver, USA. [Poster]
Web of Science

 

Leithner, K; Hrzenjak, A; Trötzmüller, M; Moustafa, T; Köfeler, HC; Wohlkoenig, C; Stacher, E; Lindenmann, J; Harris, AL; Olschewski, A; Olschewski, H PCK2 activation mediates an adaptive response to glucose depletion in lung cancer.
Oncogene. 2015; 34(8):1044-1050
Web of Science PubMed FullText FullText_MUG

 

Petru, E; Singer, CF; Polterauer, S; Galid, A; Schauer, C; Klocker, J; Seifert, M; Reinthaller, A; Benedicic, C; Hubalek, M; Hefler, L; Marth, C; Scholl-Firon, T; Bogner, G; Zeimet, AG Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement.
Wien Med Wochenschr. 2015; 165(19-20):387-394
Web of Science PubMed FullText FullText_MUG

 

Popper, HH Lung adenocarcinomas: comparison between mice and men.
Methods Mol Biol. 2015; 1267(2):19-43
PubMed FullText FullText_MUG

 

Schimek, MG; Budinská, E; Kugler, KG; Švendová, V; Ding, J; Lin, S TopKLists: a comprehensive R package for statistical inference, stochastic aggregation, and visualization of multiple omics ranked lists.
Stat Appl Genet Mol Biol. 2015; 14(3):311-316 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Grah, JJ; Katalinic, D; Juretic, A; Santek, F; Samarzija, M Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer.
Tumori. 2014; 100(1):60-68
Web of Science PubMed FullText FullText_MUG

 

Leithner, K; Wohlkoenig, C; Stacher, E; Lindenmann, J; Hofmann, NA; Gallé, B; Guelly, C; Quehenberger, F; Stiegler, P; Smolle-Jüttner, FM; Philipsen, S; Popper, HH; Hrzenjak, A; Olschewski, A; Olschewski, H Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model - role of tumor stroma cells.
BMC Cancer. 2014; 14(1):40-40 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pircher, A; Gamerith, G; Amann, A; Reinold, S; Popper, H; Gächter, A; Pall, G; Wöll, E; Jamnig, H; Gastl, G; Wolf, AM; Hilbe, W; Wolf, D Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.
Lung Cancer. 2014; 85(1): 81-87.
Web of Science PubMed FullText FullText_MUG

 

Pircher, A; Manzl, C; Fiegl, M; Popper, H; Pirker, R; Hilbe, W Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Lung Cancer. 2014; 83(3): 408-410. (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Posch, F; Setinek, U; Flores, RM; Bernhard, D; Hannigan, GE; Mueller, MR; Watzka, SB Serum integrin-linked kinase (sILK) concentration and survival in non-small cell lung cancer: a pilot study.
Clin Transl Oncol. 2014; 16(5): 455-462.
Web of Science PubMed FullText FullText_MUG

 

2013

Graziano, SL; Lacas, B; Vollmer, R; Kratzke, R; Popper, H; Filipits, M; Seymour, L; Shepherd, FA; Rosell, R; Veillard, AS; Taron, M; Pignon, JP Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.
Lung Cancer. 2013; 82(1):149-155 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Moldvay, J; Barbai, T; Bogos, K; Piurko, V; Fillinger, J; Popper, HH; Tímár, J EGFR autophosphorylation but not protein score correlates with histologic and molecular subtypes in lung adenocarcinoma.
Diagn Mol Pathol. 2013; 22(4):204-209
Web of Science PubMed FullText FullText_MUG

 

Olaussen, KA; Adam, J; Vanhecke, E; Vielh, P; Pirker, R; Friboulet, L; Popper, H; Robin, A; Commo, F; Thomale, J; Kayitalire, L; Filipits, M; Le Chevalier, T; André, F; Brambilla, E; Soria, JC PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Lung Cancer. 2013; 80(2):216-222 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Thunnissen, E; Kerr, KM; Herth, FJ; Lantuejoul, S; Papotti, M; Rintoul, RC; Rossi, G; Skov, BG; Weynand, B; Bubendorf, L; Katrien, G; Johansson, L; Lpez-Ros, F; Ninane, V; Olszewski, W; Popper, H; Jaume, S; Schnabel, P; Thiberville, L; Laenger, F The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group.
Lung Cancer. 2012; 76(1):1-18
Web of Science PubMed FullText FullText_MUG

 

2011

Kriegshäuser, G; Fabjani, G; Ziegler, B; Zöchbauer-Müller, S; End, A; Zeillinger, R Biochip-based detection of KRAS mutation in non-small cell lung cancer.
Int J Mol Sci. 2011; 12(12): 8530-8538. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Popper, H; Wrba, F; Gruber-Mösenbacher, U; Hulla, W; Pirker, R; Hilbe, W; Studnicka, M; Mohn-Staudner, A; Ploner, F; und die Arbeitsgruppe Pulmopathologie der ÖGP-IAP Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer.
Wien Klin Wochenschr. 2011; 123(9-10):316-321
Web of Science PubMed FullText FullText_MUG

 

Watzka, SB; Posch, F; Hochmair, M; Setinek, U; Köstler, WJ; Müller, MR Resistance to EGFR targeting therapies in lung cancer.
Minerva Chir. 2011; 66(5): 483-494.
Web of Science PubMed

 

2010

Kriegshäuser, G; Auner, V; Zeillinger, R New and potential clinical applications of KRAS as a cancer biomarker.
Expert Opin Med Diagn. 2010; 4(5):383-395
PubMed FullText FullText_MUG

 

Pircher, A; Ploner, F; Popper, H; Hilbe, W Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients.
Lung Cancer. 2010; 69(3): 265-271.
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Smolle-Juettner, FM; Maier, A; Lindenmann, J; Matzi, V; Neubock, N Resection in Stage I/II Non-Small Cell Lung Cancer
FRONT RADIAT THER ONCOL. 2010; 42: 71-77.
Web of Science PubMed

 

2009

Leithner, K; Stacher, E; Wurm, R; Ploner, F; Quehenberger, F; Wohlkoenig, C; Bálint, Z; Polachova, J; Olschewski, A; Samonigg, H; Popper, HH; Olschewski, H Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
Lung Cancer. 2009; 65(1):98-104
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2008

Grah, J; Samija, M; Juretić, A; Sarcević, B; Sobat, H Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
Coll Antropol. 2008; 32(3):731-736
Web of Science PubMed

 

2007

Filipits, M; Haddad, V; Schmid, K; Huynh, A; Dunant, A; André, F; Brambilla, E; Stahel, R; Pignon, JP; Soria, JC; Popper, HH; Le Chevalier, T; Pirker, R Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program.
Clin Cancer Res. 2007; 13(13): 3892-3898. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Weitere 50 Treffer anzeigen
© Med Uni Graz Impressum